Table VII.
Covariate Parameters Estimated from the Final Population Pharmacokinetic Model Using Data from Both the ECL Assay and the ELISA
| Parameter | ECL | ELISA | ||
|---|---|---|---|---|
| Estimate | Bayesian 95% CDI | Estimate | Bayesian 95% CDI | |
| Continuous covariatesa | ||||
| CLL~weight | 0.339 | (0.264 to 0.406) | 0.368 | (0.306 to 0.433) |
| CLL~albumin | − 1.03 | (− 1.12 to − 0.940) | − 1.18 | (− 1.24 to − 1.13) |
| CLL~fecal calprotectin | 0.0279 | (0.0204 to 0.0349) | 0.0312 | (0.0257 to 0.0368) |
| CD CLL~CDAI | − 0.0582 | (− 0.151 to 0.0337) | − 0.0558 | (− 0.144 to 0.0311) |
| UC CLL~partial Mayo score | 0.0543 | (− 0.0227 to 0.132) | 0.0406 | (− 0.0339 to 0.115) |
| CLL~age | − 0.0190 | (− 0.0673 to 0.0294) | − 0.0339 | (− 0.0778 to 0.0103) |
| Vc~weight | 0.456 | (0.409 to 0.502) | 0.469 | (0.427 to 0.511) |
| Vp~weight | 1.00 fixed | — | 1.00 fixed | (1.00 to 1.00) |
| Vmax~weight | 0.750 fixed | — | 0.75 fixed | (0.75 to 0.75) |
| Q~weight | 0.750 fixed | — | 0.75 fixed | (0.75 to 0.72) |
| Categorical covariatesb | ||||
| CLL~TNF | 1.05 | (1.01 to 1.09) | 1.04 | (1.01 to 1.07) |
| CLL~ADASUB | 1.10 | (1.03 to 1.17) | 1.12 | (1.05 to 1.2) |
| CLL~AZA full duration | 0.998 | (0.960 to 1.04) | 0.992 | (0.958 to 1.03) |
| CLL~AZA unknown duration | 0.963 | (0.876 to 1.05) | 0.965 | (0.886 to 1.05) |
| CLL~MP full duration | 1.05 | (0.949 to 1.17) | 1.07 | (0.97 to 1.18) |
| CLL~MP unknown duration | 1.12 | (0.989 to 1.26) | 1.09 | (0.974 to 1.22) |
| CLL~MTX full duration | 1.02 | (0.923 to 1.12) | 1.02 | (0.933 to 1.11) |
| CLL~MTX unknown duration | 1.02 | (0.871 to 1.20) | 0.951 | (0.825 to 1.09) |
| CLL~AMINO full duration | 1.01 | (0.969 to 1.05) | 1.02 | (0.984 to 1.06) |
| CLL~AMINO unknown duration | 0.959 | (0.903 to 1.02) | 0.972 | (0.922 to 1.02) |
| Vc~diagnosis (CD or UC) | 1.01 | (0.985 to 1.04) | 1.01 | (0.989 to 1.03) |
AMINO aminosalicylate adjuvant therapy, ADA vedolizumab anti-drug antibody, ADASUB patient-level ADA incidence indicator, AZA azathioprine adjuvant therapy, CD Crohn’s disease, CDAI Crohn’s Disease Activity Index, CDI credible interval, CLL linear clearance, ECL electrochemiluminescence, ELISA enzyme-linked immunosorbent assay, MP mercaptopurine adjuvant therapy, MTX methotrexate adjuvant therapy, Q intercompartmental clearance, TNF tumor necrosis factor, UC, ulcerative colitis, Vc central compartment volume, Vp peripheral compartment volume, Vmax maximum elimination rate
aNull effect = 0
bNull effect = 1